login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
BEONE MEDICINES LTD-ADR (ONC) Stock News
USA
- NASDAQ:ONC -
US07725L1026
-
ADR
326.06
USD
-2.65 (-0.81%)
Last: 9/26/2025, 8:20:48 PM
326.06
USD
0 (0%)
After Hours:
9/26/2025, 8:20:48 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ONC Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Benzinga
Analyst Expectations For BeOne Medicines's Future
17 days ago - By: Investor's Business Daily
- Mentions:
PFE
NYT
LLY
ZLAB
...
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
17 days ago - By: Benzinga
- Mentions:
ACTU
CAMP
INTS
REVB
...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
2 months ago - By: The Motley Fool
BeOne Medicines (ONC) Q2 EPS Soars 924%
a month ago - By: BeOne Medicines Ltd.
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
a month ago - By: Yahoo Finance
BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025
a month ago - By: BeOne Medicines Ltd.
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025
a month ago - By: BeOne Medicines Ltd.
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
a month ago - By: BeOne Medicines Ltd.
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
a month ago - By: BeOne Medicines Ltd.
European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
2 months ago - By: Zacks Investment Research
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say
2 months ago - By: BeOne Medicines Ltd.
BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates
2 months ago - By: BeOne Medicines Ltd.
BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia
2 months ago - By: BeOne Medicines Ltd.
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment
2 months ago - By: Yahoo Finance
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
2 months ago - By: BeOne Medicines Ltd.
BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6
3 months ago - By: BeOne Medicines Ltd.
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
3 months ago - By: Yahoo Finance
- Mentions:
MS
JPM
BeOne Medicines price target raised to $330 from $313 at Morgan Stanley
3 months ago - By: BeOne Medicines Ltd.
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
3 months ago - By: BeOne Medicines Ltd.
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
4 months ago - By: BeOne Medicines Ltd.
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
4 months ago - By: BeOne Medicines Ltd.
U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
4 months ago - By: BeOne Medicines Ltd.
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
4 months ago - By: Yahoo Finance
- Mentions:
SRPT
ALNY
AKBA
PLTR
...
The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation
4 months ago - By: Yahoo Finance
- Mentions:
AAPL
JPM
VZ
TSLA
...
Apple App Store Sales Jump In May, Boosting Outlook For Services Growth
Please enable JavaScript to continue using this application.